HAMP and chronic kidney disease: Oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) including roxadustat, vadadustat, desidustat, daprodustat and molidustat were shown to significantly increase hemoglobin levels and total iron binding capacity concomitant to an decrease in hepcidin and ferritin levels in patients with anemia and chronic kidney disease [320].